This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Nerve damage	Glycogen synthase kinase 3 β (GSK3B)	<p><i>In vitro</i> and mouse studies suggest GSK3B inhibition could help treat peripheral nerve injury. In a mouse model of facial nerve crush, intraperitoneal injection with the GSK3B inhibitor lithium chloride (LiCl) promoted remyelination and accelerated recovery of whisker movements compared with saline control injection. In a mouse model of sciatic nerve crush, oral LiCl promoted remyelination compared with saline control. Next steps include testing LiCl in clinical trials.</p> <p>DiaMedica Inc.'s GSK3B inhibitor DM-99 is in Phase II testing to treat diabetes.</p> <p>Neurim Pharmaceuticals Ltd.'s GSK3B inhibitor, Neu-120, is in Phase II testing to treat Parkinson's disease (PD).</p> <p>SciBX 5(10); doi:10.1038/scibx.2012.260 Published online March 8, 2012</p>	Unpatented; unavailable for licensing	<p>Makoukji, J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 21, 2012; doi:10.1073/pnas.1121367109</p> <p>Contact: Charbel Massaad, University Paris Descartes, Paris, France e-mail: charbel.massaad@parisdescartes.fr</p>